Co-Diagnostics Will Join Global Health Roundtable
The company will discuss Ebola response technologies during a New York City event on September 22, 2026.
Updated on Sept. 21, 2026 in Biotech
Co-Diagnostics Chief Commercialization Officer Seth Egan will participate in a September 22, 2026, roundtable hosted by the Global Health Technologies Coalition. The discussion in New York City will focus on developing partnerships and effective systems to improve responses to the ongoing Ebola outbreak.
Why it matters
The roundtable aims to bridge the gap between early warning systems and actual outbreak response for high-stakes diseases like Ebola. By evaluating new sample-preparation workflows, the participants hope to improve the speed and accessibility of molecular virus detection.
Co-Diagnostics is evaluating its PCR platform in combination with ReadyGo Diagnostics' GoCollect blood-based molecular sample-preparation technology. The system is intended for decentralized detection but is not yet cleared by the FDA or available for sale.
The players
Seth Egan
He serves as the Chief Commercialization Officer for Co-Diagnostics.
Co-Diagnostics
This molecular diagnostics company is headquartered in Salt Lake City and specializes in platform development.
Global Health Technologies Coalition
This organization advocates for research and development to address global health threats and disease outbreaks.
CoSara Diagnostics
This is a joint venture that creates diagnostic tests, including specific assays for Ebola virus variants.
ReadyGo Diagnostics
This technology firm focuses on developing sample-preparation equipment for molecular diagnostic applications.
The details
The collaboration seeks to create a streamlined workflow that simplifies how laboratories prepare samples for virus detection. Co-Diagnostics joint venture CoSara Diagnostics has already developed specific pan-Ebola and Bundibugyo virus tests currently under review by researchers in India.
Timeline
September 21, 2026: Co-Diagnostics announces participation in the roundtable.
September 22, 2026: The roundtable discussion takes place in New York City.
The Tech Race
This effort represents a broader industry move toward decentralized, rapid diagnostics capable of operating in resource-limited environments. It follows the precedent set by the Global Health Technologies Coalition's outbreak response research agenda, which prioritizes accessible molecular testing tools.
The development of these decentralized tests could eventually lower the barrier to entry for rapid viral detection in remote or clinical settings. However, as the platform lacks current FDA authorization, it remains unavailable for immediate use by healthcare providers.
The takeaway
Advancements in decentralized molecular testing remain critical for modernizing the global response to viral outbreaks. Achieving these technical milestones depends on successful integration between new sample-preparation methods and existing PCR platforms.
Further reading
For more information on diagnostic advancements, visit the Biotech section.
